A role for astrocytes in inherited amyotrophic lateral sclerosis (ALS) linked to SOD1 mutations has been considered in several contexts, both in patients and animal models of the disease. Astrocytes expressing ALS-linked mutant SOD1 proteins produce and release one or more as yet uncharacterized soluble components that can accelerate motor neuron death in vitro. Focal loss of the astrocytic glutamate transporter EAAT2 (a.k.a. GLT-1) in the diseased spinal cord and failure of normal glutamate re-uptake in ALS patients and animal models support glutamate-dependent excitotoxicity as a component of the disease. In the previous funding cycle, we have found that EAAT2 is selectively cleaved by caspase-3 in the spinal cord of mutant SOD1 (SOD1-G93A) transgenic mice model of ALS and that the C-terminal EAAT2 fragment derived from this cleavage (termed CTE fragment) is conjugated to SUMO-1 (small ubiquitin modifier protein) and accumulates in the disease, beginning already at pre-symptomatic age. The formation of this CTE-SUMO1 fragment is distinctive of ALS as it does not occur in other neurodegenerative diseases such as Huntington's disease. This evidence suggests that ALS mechanisms target selectively EAAT2. Based on a new set of preliminary observations we hypothesize that in addition to the general excitotoxicity ensued by impaired function of the glutamate transporter EAAT2, the accumulation in spinal cord astrocytes of the CTE-SUMO1 fragment plays a direct role in the pathogenesis and/or progression of this disease. In this application we propose to study in vitro and in vivo the implications on motor neuron death and the ALS phenotype of CTE-SUMO1 astrocytic accumulation. We have designed four specific aims:
In Aim 1 we will characterize SUMOylation of EAAT2 in mutSOD1 mice model of ALS and its functional implications.
In Aims 2 - 4 will define in vitro and in vivo the localization and pathophysiological implications of the EAAT2-derived fragment CTE-SUMO1 in the context of motor neuron death linked to ALS. Our overarching goal is to identify the molecular mechanisms underlying glutamate transporter dysfunction in ALS at post-translational levels.

Public Health Relevance

Amyotrophic lateral sclerosis (ALS) is one of the most devastating and lethal progressive neuromuscular disorders. Over 30,000 people are living with ALS in the United States and approximately 5,000 Americans will be diagnosed with ALS this year. There is a growing body of evidence indicating that a defective re-uptake protein called glutamate transporter EAAT2 contributes to the progression of this neuromuscular disease. In this application we propose to study the mechanisms of impairment of these re-uptake proteins in ALS to unravel possible molecular targets for future therapeutic intervention.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS044292-08
Application #
7906813
Study Section
Special Emphasis Panel (ZRG1-BDCN-Y (04))
Program Officer
Gubitz, Amelie
Project Start
2002-07-01
Project End
2012-07-31
Budget Start
2010-08-01
Budget End
2012-07-31
Support Year
8
Fiscal Year
2010
Total Cost
$424,875
Indirect Cost
Name
Thomas Jefferson University
Department
Neurosciences
Type
Schools of Medicine
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Maimon, Roy; Ionescu, Ariel; Bonnie, Avichai et al. (2018) miR126-5p Downregulation Facilitates Axon Degeneration and NMJ Disruption via a Non-Cell-Autonomous Mechanism in ALS. J Neurosci 38:5478-5494
Rosenblum, Lauren Taylor; Trotti, Davide (2017) EAAT2 and the Molecular Signature of Amyotrophic Lateral Sclerosis. Adv Neurobiol 16:117-136
Rosenblum, Lauren Taylor; Shamamandri-Markandaiah, Shashirekha; Ghosh, Biswarup et al. (2017) Mutation of the caspase-3 cleavage site in the astroglial glutamate transporter EAAT2 delays disease progression and extends lifespan in the SOD1-G93A mouse model of ALS. Exp Neurol 292:145-153
Wen, Xinmei; Tan, Wenzhi; Westergard, Thomas et al. (2014) Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron 84:1213-25
Tan, Wenzhi; Pasinelli, Piera; Trotti, Davide (2014) Role of mitochondria in mutant SOD1 linked amyotrophic lateral sclerosis. Biochim Biophys Acta 1842:1295-301
Foran, E; Rosenblum, L; Bogush, A et al. (2014) Sumoylation of the astroglial glutamate transporter EAAT2 governs its intracellular compartmentalization. Glia 62:1241-53
Foran, Emily; Rosenblum, Lauren; Bogush, Alexey I et al. (2013) Sumoylation of critical proteins in amyotrophic lateral sclerosis: emerging pathways of pathogenesis. Neuromolecular Med 15:760-70
Jablonski, Michael R; Jacob, Dena A; Campos, Christopher et al. (2012) Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS. Neurobiol Dis 47:194-200
Foran, Emily; Bogush, Alexey; Goffredo, Michael et al. (2011) Motor neuron impairment mediated by a sumoylated fragment of the glial glutamate transporter EAAT2. Glia 59:1719-31
Boston-Howes, William; Williams, Eric O; Bogush, Alexey et al. (2008) Nordihydroguaiaretic acid increases glutamate uptake in vitro and in vivo: therapeutic implications for amyotrophic lateral sclerosis. Exp Neurol 213:229-37

Showing the most recent 10 out of 13 publications